# **Product** Data Sheet

### ML-9

Cat. No.: HY-100932 CAS No.: 105637-50-1 Molecular Formula:  $C_{15}H_{18}Cl_2N_2O_2S$ 

Molecular Weight: 361.29 Target: Myosin Pathway: Cytoskeleton

Storage: 4°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

#### **SOLVENT & SOLUBILITY**

In Vitro DMSO: 83.33 mg/mL (230.65 mM; Need ultrasonic)

 $H_2O : \ge 5 \text{ mg/mL } (13.84 \text{ mM})$ 

\* "≥" means soluble, but saturation unknown.

| Preparing<br>Stock Solutions | Solvent Mass<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|-------------------------------|-----------|------------|------------|
|                              | 1 mM                          | 2.7679 mL | 13.8393 mL | 27.6786 mL |
|                              | 5 mM                          | 0.5536 mL | 2.7679 mL  | 5.5357 mL  |
|                              | 10 mM                         | 0.2768 mL | 1.3839 mL  | 2.7679 mL  |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.76 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.76 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.76 mM); Clear solution

#### **BIOLOGICAL ACTIVITY**

Description

ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity  $^{[3]}$ . ML-9 inhibits inhibits MLCK, PKA and PKC activity with  $K_i$  values of 4, 32 and 54  $\mu$ M, respectively<sup>[1]</sup>. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation<sup>[3]</sup>.

In Vitro

ML9 (0-100 μM; 0-24 hours) has no reduction in cardiomyocyte viability, 50-100 μM significantly induces cell death<sup>[2]</sup>. ML9 (50 μM; 1-4 hours) significantly increases cleaved caspase-3 levels, decreased STIM1 protein levels by about 42%<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| Cell Viability Assay <sup>[1]</sup> |   |  |
|-------------------------------------|---|--|
| Cell Line:                          | Neonatal rat ventricular myocytes (NRVM) cells              |  |
| Concentration:                      | 0, 10, 50 and 100 μM  |  |
| Incubation Time:                    | 0, 1, 4, 8 and 24 hours                                     |  |
| Result:                             | Decreased cell viability at 50-100 μM concentration.        |  |
| Apoptosis Analysis <sup>[1]</sup>   |   |  |
| Cell Line:                          | Neonatal rat ventricular myocytes (NRVM) cells              |  |
| Concentration:                      | 50 μΜ   |  |
| Incubation Time:                    | 1, 4 and 8 hours  |  |
| Result:                             | Induced cardiomyocyte death through necrosis and apoptosis. |  |

## **CUSTOMER VALIDATION**

• bioRxiv. 2023 Feb 5.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

- [1]. Ito S, et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis. Eur J Pharmacol. 2004 Feb 23;486(3):325-33.
- [2]. Shaikh S, et al. The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content. Toxicol In Vitro. 2018 Apr; 48:121-127.
- [3]. Kondratskyi A1, et al.Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. Cell Death Dis. 2014 Apr 24;5:e1193.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA